Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dronabinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 10/20 | 1.00 |
| ▸ | CNR2 | P34972 | 16/20 | 1.00 |
| ▸ | ABHD12 | Q8N2K0 | 3/20 | 1.00 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 1.00 |
| ▸ | FAAH | O00519 | 2/20 | 1.00 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | LDHA | P00338 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 1/20 | 1.00 |
| ▸ | GPR18 | Q14330 | 1/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.86 |
| ▸ | HTR1A | P08908 | 1/20 | 0.86 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.86 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.86 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.86 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dronabinol SCHEMBL29390424 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL13394311 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL29349828 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL11375978 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL1227386 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL13214137 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL24702729 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL4609 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL22705549 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL29410178 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544390-B2 | Methods to refine cannabinoids | Natural Extraction Systems, LLC (US) | 2026-02-10 | — | — | US | claimed |
| US-20240131040-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2024-04-25 | — | — | US | claimed |
| WO-2023064318-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC (US) | 2023-04-20 | — | — | WO | claimed |
| US-20230073802-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2023-03-09 | — | — | US | claimed |
| US-20220249434-A1 | Reversal of Baldness in Men and Women through Cannabinoid Receptor Activation | POSTREL RICHARD (US) | 2022-08-11 | — | — | US | claimed |
| WO-2022026960-A1 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | Natural Extraction Systems, LLC (US) | 2022-02-03 | — | — | WO | claimed |
| US-20210360947-A1 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | Natural Extraction Systems, LLC | 2021-11-25 | — | — | US | claimed |
| WO-2021158714-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021074399-A1 | CONTROLLED RELEASE FORMULATIONS OF HIGHLY LIPOPHILIC PHYSIOLOGICALLY ACTIVE SUBSTANCES | ADD ADVANCED DRUG DELIVERY TECHNOLOGIES LTD. (CH) | 2021-04-22 | — | — | WO | claimed |
| US-20200078333-A1 | Healthier Aging in Domesticated Animals | POSTREL RICHARD (US) | 2020-03-12 | — | — | US | claimed |
| WO-2014140231-A1 | ABUSE RESISTANT CAPSULE | WENGNER SIMONE (DE) | 2014-09-18 | — | — | WO | claimed |
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | claimed |
| EP-2026798-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | Solvay Pharmaceuticals GmbH (DE) | 2009-02-25 | — | — | EP | claimed |
| EP-2012775-A1 | USE OF CBX CANNABINOID RECEPTOR MODULATORS AS POTASSIUM CHANNEL MODULATORS | Solvay Pharmaceuticals GmbH (DE) | 2009-01-14 | — | — | EP | claimed |
| WO-2007125049-A1 | USE OF CBX CANNABINOID RECEPTOR MODULATORS AS POTASSIUM CHANNEL MODULATORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-08 | — | — | WO | claimed |
| WO-2007125048-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-08 | — | — | WO | claimed |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | claimed |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | claimed |
| EP-1558257-A1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | Grünenthal GmbH (DE) | 2005-08-03 | — | — | EP | claimed |
| WO-2004037259-A1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | Grünenthal GmbH (DE) | 2004-05-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | CNR2, CNR1, KCNN1 | CNR1 2/4885CNR2 1/4885ABHD12 1467/4885 |
| US-20240131040-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | CNR1, CNR2, OPRD1 | CNR1 1/4885CNR2 2/4885ABHD12 3094/4885 |
| US-20210360947-A1 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885ABHD12 741/4885 |
| US-12544390-B2 | Methods to refine cannabinoids | CNR2, CNR1, CCKAR | CNR1 2/4885CNR2 1/4885ABHD12 4131/4885 |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | CNR1, CNR2, KCNJ11 | CNR1 1/4885CNR2 2/4885ABHD12 2034/4885 |
| US-20230073802-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885ABHD12 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.